This is consistent with previous findings showing that increased Tau levels in a mouse model of Alzheimer’s disease do not alter APP steady-state levels or affect Aβ pathology [43]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.